Last reviewed · How we verify

NCT04975113

The Effects of Progressive Neuromuscular Exercise Program and Taping on Muscle Strength and Pain in Patellofemoral Pain

Completed NA Last updated 23 July 2021
What this trial tests

NA trial testing progressive neuromuscular exercise program in Patellofemoral Pain Syndrome in 30 participants. Completed in 20 December 2015.

Timeline
1 August 2015
Primary endpoint
20 December 2015
20 December 2015

Quick facts

Lead sponsorAnkara Yildirim Beyazıt University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment30
Start date1 August 2015
Primary completion20 December 2015
Estimated completion20 December 2015
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ankara Yildirim Beyazıt University

Who can join

Adults 20 to 45, female only, with Patellofemoral Pain Syndrome or Kinesiotape. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neuromuscular exercise and taping are widely used in the rehabilitation of Patellofemoral Pain. The aim of this study was to investigate the effects of corrective kinesio taping applied on patellofemoral joint and foot in addition to a progressive neuromuscular exercise program in women with Patellofemoral Pain on knee pain and muscle strength.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Patellofemoral Pain Syndrome

Currently open trials in the same condition.

Other Ankara Yildirim Beyazıt University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04975113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing